JP2011528897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528897A5 JP2011528897A5 JP2011519187A JP2011519187A JP2011528897A5 JP 2011528897 A5 JP2011528897 A5 JP 2011528897A5 JP 2011519187 A JP2011519187 A JP 2011519187A JP 2011519187 A JP2011519187 A JP 2011519187A JP 2011528897 A5 JP2011528897 A5 JP 2011528897A5
- Authority
- JP
- Japan
- Prior art keywords
- tuberculosis
- prevention
- treatment
- protein sequence
- rv1753c protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008827 tuberculosis Diseases 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 22
- 230000002265 prevention Effects 0.000 claims 22
- 101100030444 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) PPE24 gene Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 230000002163 immunogen Effects 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 206010065048 Latent tuberculosis Diseases 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 230000007420 reactivation Effects 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000036981 active tuberculosis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8369208P | 2008-07-25 | 2008-07-25 | |
| US61/083,692 | 2008-07-25 | ||
| PCT/EP2009/059586 WO2010010180A1 (en) | 2008-07-25 | 2009-07-24 | Novel compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528897A JP2011528897A (ja) | 2011-12-01 |
| JP2011528897A5 true JP2011528897A5 (OSRAM) | 2012-09-06 |
| JP5824360B2 JP5824360B2 (ja) | 2015-11-25 |
Family
ID=41172233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519187A Active JP5824360B2 (ja) | 2008-07-25 | 2009-07-24 | 新規化合物および方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9315556B2 (OSRAM) |
| EP (1) | EP2315597B1 (OSRAM) |
| JP (1) | JP5824360B2 (OSRAM) |
| KR (2) | KR20110060891A (OSRAM) |
| CN (2) | CN102164612B (OSRAM) |
| AU (1) | AU2009273133B2 (OSRAM) |
| BR (1) | BRPI0916705A2 (OSRAM) |
| CA (1) | CA2731549C (OSRAM) |
| CO (1) | CO6400198A2 (OSRAM) |
| CY (1) | CY1119737T1 (OSRAM) |
| EA (1) | EA022203B1 (OSRAM) |
| ES (1) | ES2647321T3 (OSRAM) |
| HR (1) | HRP20171694T1 (OSRAM) |
| HU (1) | HUE037121T2 (OSRAM) |
| IL (1) | IL210588A0 (OSRAM) |
| LT (1) | LT2315597T (OSRAM) |
| MX (1) | MX2011000981A (OSRAM) |
| NO (1) | NO2315597T3 (OSRAM) |
| PL (1) | PL2315597T3 (OSRAM) |
| PT (1) | PT2315597T (OSRAM) |
| SG (1) | SG10201505149WA (OSRAM) |
| SI (1) | SI2315597T1 (OSRAM) |
| UA (1) | UA107180C2 (OSRAM) |
| WO (1) | WO2010010180A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2315834T3 (pl) | 2008-07-25 | 2018-12-31 | Glaxosmithkline Biologicals S.A. | Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania |
| GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
| WO2013090897A1 (en) * | 2011-12-15 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Using adaptive immunity to detect drug resistance |
| CN103467582A (zh) * | 2012-06-08 | 2013-12-25 | 同济大学 | 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用 |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| WO2018104313A1 (en) | 2016-12-07 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Novel process |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| EP3630176A1 (en) | 2017-05-30 | 2020-04-08 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| EP3717001A1 (en) | 2017-12-01 | 2020-10-07 | GlaxoSmithKline Biologicals S.A. | Saponin purification |
| US20220218811A1 (en) * | 2019-04-17 | 2022-07-14 | Codiak Biosciences, Inc. | Methods of treating tuberculosis |
| US20220235095A1 (en) | 2019-06-05 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Saponin purification |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4016146A (en) * | 1974-12-10 | 1977-04-05 | Biological Developments, Inc. | Phenethylamine antigenic conjugates, their preparation, antibodies, and use |
| EP0671948B1 (en) | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6613881B1 (en) | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
| CA2326598C (en) | 1998-04-07 | 2014-06-10 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| US7083796B2 (en) | 2000-06-20 | 2006-08-01 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US6291013B1 (en) * | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
| AU7383500A (en) | 1999-09-17 | 2001-04-17 | United States Government, As Represented By The Department Of Veteran's Affairs | Virulence genes of m. marinum and m. tuberculosis |
| AU779978B2 (en) | 1999-10-07 | 2005-02-24 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| WO2001062893A2 (en) | 2000-02-25 | 2001-08-30 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| WO2002074903A2 (en) | 2001-02-22 | 2002-09-26 | Institut Pasteur | Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| AU2003213118A1 (en) | 2002-02-15 | 2003-09-09 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US20030236393A1 (en) * | 2002-03-22 | 2003-12-25 | United States Of America Dept Of Vetrans Affairs | Virulence genes of M. marinum and M. tuberculosis |
| EP1721283B1 (en) * | 2004-02-06 | 2022-11-30 | Council of Scientific and Industrial Research | Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential |
| HRP20120331T1 (hr) | 2005-04-29 | 2012-05-31 | Glaxosmithkline Biologicals Sa | Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis |
| WO2008007942A1 (en) | 2006-07-10 | 2008-01-17 | Het Nederlands Kanker Instituut | Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof |
| AU2008223951B2 (en) * | 2007-03-02 | 2014-03-27 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
| WO2010010178A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A | The tuberculosis rv2707c protein, compositions and uses thereof |
| PL2315834T3 (pl) | 2008-07-25 | 2018-12-31 | Glaxosmithkline Biologicals S.A. | Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania |
| LT2315773T (lt) * | 2008-07-25 | 2016-11-10 | Glaxosmithkline Biologicals S.A. | Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui |
| BRPI1006452A2 (pt) | 2009-04-24 | 2016-12-27 | Statens Seruminstitut | vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo |
| US8367055B2 (en) | 2009-05-14 | 2013-02-05 | Wisconsin Alumni Research Foundation | Immunogenic compositions against tuberculosis |
| CN102869372B (zh) | 2010-01-27 | 2016-01-20 | 葛兰素史密丝克莱恩生物有限公司 | 经修饰的结核抗原 |
-
2009
- 2009-07-24 EP EP09781058.4A patent/EP2315597B1/en active Active
- 2009-07-24 CN CN200980138416.7A patent/CN102164612B/zh active Active
- 2009-07-24 PT PT97810584T patent/PT2315597T/pt unknown
- 2009-07-24 CA CA2731549A patent/CA2731549C/en active Active
- 2009-07-24 UA UAA201100362A patent/UA107180C2/uk unknown
- 2009-07-24 CN CN201711306994.XA patent/CN108059660A/zh active Pending
- 2009-07-24 EA EA201100071A patent/EA022203B1/ru not_active IP Right Cessation
- 2009-07-24 BR BRPI0916705A patent/BRPI0916705A2/pt not_active Application Discontinuation
- 2009-07-24 WO PCT/EP2009/059586 patent/WO2010010180A1/en not_active Ceased
- 2009-07-24 HR HRP20171694TT patent/HRP20171694T1/hr unknown
- 2009-07-24 SG SG10201505149WA patent/SG10201505149WA/en unknown
- 2009-07-24 US US13/055,775 patent/US9315556B2/en active Active
- 2009-07-24 SI SI200931748T patent/SI2315597T1/sl unknown
- 2009-07-24 NO NO09781058A patent/NO2315597T3/no unknown
- 2009-07-24 AU AU2009273133A patent/AU2009273133B2/en not_active Ceased
- 2009-07-24 HU HUE09781058A patent/HUE037121T2/hu unknown
- 2009-07-24 LT LTEP09781058.4T patent/LT2315597T/lt unknown
- 2009-07-24 KR KR1020117004475A patent/KR20110060891A/ko not_active Ceased
- 2009-07-24 KR KR1020167001375A patent/KR20160013262A/ko not_active Ceased
- 2009-07-24 MX MX2011000981A patent/MX2011000981A/es active IP Right Grant
- 2009-07-24 ES ES09781058.4T patent/ES2647321T3/es active Active
- 2009-07-24 PL PL09781058T patent/PL2315597T3/pl unknown
- 2009-07-24 JP JP2011519187A patent/JP5824360B2/ja active Active
-
2011
- 2011-01-12 IL IL210588A patent/IL210588A0/en unknown
- 2011-01-27 CO CO11009236A patent/CO6400198A2/es not_active Application Discontinuation
-
2016
- 2016-03-11 US US15/067,469 patent/US9750794B2/en not_active Expired - Fee Related
-
2017
- 2017-11-13 CY CY20171101185T patent/CY1119737T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528896A5 (OSRAM) | ||
| JP2011528895A5 (OSRAM) | ||
| JP2011528897A5 (OSRAM) | ||
| JP2012126742A5 (OSRAM) | ||
| JP2012136541A5 (OSRAM) | ||
| JP2014051497A5 (OSRAM) | ||
| JP2014530220A5 (OSRAM) | ||
| JP2013231081A5 (OSRAM) | ||
| HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
| JP2015517488A5 (OSRAM) | ||
| JP2015517489A5 (OSRAM) | ||
| JP2013509429A5 (OSRAM) | ||
| JP2013520405A5 (OSRAM) | ||
| JP2011136997A5 (OSRAM) | ||
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| JP2008536483A5 (OSRAM) | ||
| JP2008508859A5 (OSRAM) | ||
| JP2012115277A5 (OSRAM) | ||
| JP2011511805A5 (OSRAM) | ||
| JP2012532874A5 (OSRAM) | ||
| JP2013507439A5 (OSRAM) | ||
| JP2008530245A5 (OSRAM) | ||
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| JP2011500073A5 (OSRAM) |